Breast lesion excision with needle biopsy device leaves residual carcinoma -- RSNA study.
This article was originally published in The Gray Sheet
Executive Summary
EXCISION WITH BIOPSY NEEDLE LEAVES RESIDUAL CARCINOMA in 73% of cases, researcher Laura Liberman, MD, Memorial Sloan-Kettering Cancer Center, New York City, said Dec. 2 at the Radiological Society of North America annual conference in Chicago. Reporting results of a study that used Johnson & Johnson's Mammotome percutaneous breast needle biopsy system, Liberman stated: "In this series of cancers in which percutaneous breast biopsy results in the complete removal of the mammographic lesion, surgery revealed residual carcinoma in 73%," or 11 of 15 cases, Liberman noted.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.